Endogenous antibodies contribute to macrophage-mediated demyelination in a mouse model for CMT1B

Journal of Neuroinflammation

Volumn 12, Issue 1, 2015, Pages

  Klein, Dennis ^a   Groh, Janos ^a   Weishaupt, Andreas ^a   Martini, Rudolf ^a  

^a UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

Author keywords

Adaptive immune system; Antibodies; B lymphocytes; Charcot Marie Tooth; Complement; Demyelination; Fc receptor; Macrophages

Indexed keywords

ANTIBODY; COMPLEMENT COMPONENT C3; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; DIFFERENTIATION ANTIGEN; HOMEODOMAIN PROTEIN; MONOCYTE-MACROPHAGE DIFFERENTIATION ANTIGEN; MYELIN PROTEIN; RAG-1 PROTEIN;

ADAPTIVE IMMUNITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY SPECIFICITY; ARTICLE; COMPLEMENT DEPOSITION; CONTROLLED STUDY; CRUSH TRAUMA; DEMYELINATION; ENDONEURIUM; FEMORAL NERVE; HEREDITARY MOTOR SENSORY NEUROPATHY; INNATE IMMUNITY; MACROPHAGE; MACROPHAGE ACTIVATION; MOUSE; MOUSE MODEL; NONHUMAN; PERIPHERAL NERVE; SAPHENOUS NERVE; ANALYSIS OF VARIANCE; ANIMAL; C57BL MOUSE; COMPLICATION; DEFICIENCY; DEMYELINATING DISEASES; DISEASE MODEL; FEMALE; GENETICS; HUMAN; IMMUNOLOGY; MALE; METABOLISM; PATHOLOGY; SCIATIC NEUROPATHY; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE;

ANALYSIS OF VARIANCE; ANIMALS; ANTIBODIES; ANTIGENS, DIFFERENTIATION; CHARCOT-MARIE-TOOTH DISEASE; DEMYELINATING DISEASES; DISEASE MODELS, ANIMAL; FEMALE; HOMEODOMAIN PROTEINS; HUMANS; MACROPHAGES; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MYELIN P0 PROTEIN; SCIATIC NEUROPATHY; SIGNAL TRANSDUCTION;

EID: 84928786776     PISSN: None     EISSN: 17422094     Source Type: Journal    
DOI: 10.1186/s12974-015-0267-y     Document Type: Article

References (38)

1. Patzko A, Shy ME. Update on Charcot-Marie-Tooth disease. Curr Neurol Neurosci Rep. 2011;11:78-88.
2. Johnson NE, Heatwole CR, Dilek N, Sowden J, Kirk CA, Shereff D, et al. Quality-of-life in Charcot-Marie-Tooth disease: The patient's perspective. Neuromuscul Disord. 2014;24:1018-23.
3. Schenone A, Nobbio L, Monti Bragadin M, Ursino G, Grandis M. Inherited neuropathies. Curr Treat Options Neurol. 2011;13:160-79.
4. Jerath NU, Shy ME. Hereditary motor and sensory neuropathies: understanding molecular pathogenesis could lead to future treatment strategies. Biochim Biophys Acta. 1852;2014:667-78.
5. Martini R, Klein D, Groh J. Similarities between inherited demyelinating neuropathies and Wallerian degeneration: an old repair program may cause myelin and axon perturbation under nonlesion conditions. Am J Pathol. 2013;183:655-60.
6. Kohl B, Fischer S, Groh J, Wessig C, Martini R. MCP-1/CCL2 modifies axon properties in a PMP22-overexpressing mouse model for Charcot-Marie-Tooth 1A neuropathy. Am J Pathol. 2010;176:1390-9.
7. Kohl B, Groh J, Wessig C, Wiendl H, Kroner A, Martini R. Lack of evidence for a pathogenic role of T-lymphocytes in an animal model for Charcot-Marie-Tooth disease 1A. Neurobiol Dis. 2010;38:78-84.
8. Carenini S, Maurer M, Werner A, Blazyca H, Toyka KV, Schmid CD, et al. The role of macrophages in demyelinating peripheral nervous system of mice heterozygously deficient in p0. J Cell Biol. 2001;152:301-8.
9. Fischer S, Kleinschnitz C, Müller M, Kobsar I, Ip CW, Rollins BJ, et al. Monocyte chemoattractant protein-1 is a pathogenic component in a model for a hereditary peripheral neuropathy. Mol Cell Neurosci. 2008;37:359-66.
10. Groh J, Heinl K, Kohl B, Wessig C, Greeske J, Fischer S, et al. Attenuation of MCP-1/CCL2 expression ameliorates neuropathy in a mouse model for Charcot-Marie-Tooth 1X. Hum Mol Genet. 2010;19:3530-43.
11. Groh J, Weis J, Zieger H, Stanley ER, Heuer H, Martini R. Colony-stimulating factor-1 mediates macrophage-related neural damage in a model for Charcot-Marie-Tooth disease type 1X. Brain. 2012;135:88-104.
12. Martini R, Fischer S, Lopez-Vales R, David S. Interactions between Schwann cells and macrophages in injury and inherited demyelinating disease. Glia. 2008;56:1566-77.
13. Schmid CD, Stienekemeier M, Oehen S, Bootz F, Zielasek J, Gold R, et al. Immune deficiency in mouse models for inherited peripheral neuropathies leads to improved myelin maintenance. J Neurosci. 2000;20:729-35.
14. Mäurer M, Schmid CD, Bootz F, Zielasek J, Toyka KV, Oehen S, et al. Bone marrow transfer from wild type mice reverts the beneficial effect of genetically-mediated immune deficiency in myelin mutants. Mol Cell Neurosci. 2001;17:1094-101.
15. Kobsar I, Berghoff M, Samsam M, Wessig C, Maurer M, Toyka KV, et al. Preserved myelin integrity and reduced axonopathy in connexin32-deficient mice lacking the recombination activating gene-1. Brain. 2003;126:804-13.
16. Vargas ME, Watanabe J, Singh SJ, Robinson WH, Barres BA. Endogenous antibodies promote rapid myelin clearance and effective axon regeneration after nerve injury. Proc Natl Acad Sci U S A. 2010;107:11993-8.
17. Giese KP, Martini R, Lemke G, Soriano P, Schachner M. Mouse P0 gene disruption leads to hypomyelination, abnormal expression of recognition molecules, and degeneration of myelin and axons. Cell. 1992;71:565-76.
18. Chen J, Trounstine M, Alt FW, Young F, Kurahara C, Loring JF, et al. Immunoglobulin gene rearrangement in B cell deficient mice generated by targeted deletion of the JH locus. Int Immunol. 1993;5:647-56.
19. Mombaerts P, Iacomini J, Johnson RS, Herrup K, Tonegawa S, Papaioannou VE. RAG-1-deficient mice have no mature B and T lymphocytes. Cell. 1992;68:869-77.
20. Klein D, Groh J, Wettmarshausen J, Martini R. Nonuniform molecular features of myelinating Schwann cells in models for CMT1: distinct disease patterns are associated with NCAM and c-Jun upregulation. Glia. 2014;62:736-50.
21. Goodyear CS, O'Hanlon GM, Plomp JJ, Wagner ER, Morrison I, Veitch J, et al. Monoclonal antibodies raised against Guillain-Barre syndrome-associated Campylobacter jejuni lipopolysaccharides react with neuronal gangliosides and paralyze muscle-nerve preparations. J Clin Invest. 1999;104:697-708.
22. Willison HJ, Halstead SK, Beveridge E, Zitman FM, Greenshields KN, Morgan BP, et al. The role of complement and complement regulators in mediating motor nerve terminal injury in murine models of Guillain-Barre syndrome. J Neuroimmunol. 2008;201-202:172-82.
23. Willison HJ, Goodyear CS. Glycolipid antigens and autoantibodies in autoimmune neuropathies. Trends Immunol. 2013;34:453-9.
24. Ramaglia V, King RH, Nourallah M, Wolterman R, de Jonge R, Ramkema M, et al. The membrane attack complex of the complement system is essential for rapid Wallerian degeneration. J Neurosci. 2007;27:7663-72.
25. Vargas ME, Barres BA. Why is Wallerian degeneration in the CNS so slow? Annu Rev Neurosci. 2007;30:153-79.
26. Rotshenker S. Microglia and macrophage activation and the regulation of complement-receptor-3 (CR3/MAC-1)-mediated myelin phagocytosis in injury and disease. J Mol Neurosci. 2003;21:65-72.
27. Hall AB, Gakidis MA, Glogauer M, Wilsbacher JL, Gao S, Swat W, et al. Requirements for Vav guanine nucleotide exchange factors and Rho GTPases in FcgammaR- and complement-mediated phagocytosis. Immunity. 2006;24:305-16.
28. Lowell CA. Rewiring phagocytic signal transduction. Immunity. 2006;24:243-5.
29. Muller M, Berghoff M, Kobsar I, Kiefer R, Martini R. Macrophage colony stimulating factor is a crucial factor for the intrinsic macrophage response in mice heterozygously deficient for the myelin protein P0. Exp Neurol. 2007;203:55-62.
30. Chitu V, Stanley ER. Colony-stimulating factor-1 in immunity and inflammation. Curr Opin Immunol. 2006;18:39-48.
31. Martini R, Zielasek J, Toyka KV, Giese KP, Schachner M. Protein zero (P0)-deficient mice show myelin degeneration in peripheral nerves characteristic of inherited human neuropathies. Nat Genet. 1995;11:281-6.
32. Shy ME, Arroyo E, Sladky J, Menichella D, Jiang H, Xu W, et al. Heterozygous P0 knockout mice develop a peripheral neuropathy that resembles chronic inflammatory demyelinating polyneuropathy (CIDP). J Neuropathol Exp Neurol. 1997;56:811-21.
33. Ydens E, Cauwels A, Asselbergh B, Goethals S, Peeraer L, Lornet G, et al. Acute injury in the peripheral nervous system triggers an alternative macrophage response. J Neuroinflammation. 2012;9:176.
34. Martini R, Toyka KV. Immune-mediated components of hereditary demyelinating neuropathies: lessons from animal models and patients. Lancet Neurol. 2004;3:457-65.
35. Buttmann M, Kaveri S, Hartung HP. Polyclonal immunoglobulin G for autoimmune demyelinating nervous system disorders. Trends Pharmacol Sci. 2013;34:445-57.
36. Ritter C, Forster D, Albrecht P, Hartung HP, Kieseier BC, Lehmann HC. IVIG regulates BAFF expression in patients with chronic inflammatory demyelinating polyneuropathy (CIDP). J Neuroimmunol. 2014;274:225-9.
37. Derfuss T, Linington C, Hohlfeld R, Meinl E. Axo-glial antigens as targets in multiple sclerosis: implications for axonal and grey matter injury. J Mol Med. 2010;88:753-61.
38. Ng JK, Malotka J, Kawakami N, Derfuss T, Khademi M, Olsson T, et al. Neurofascin as a target for autoantibodies in peripheral neuropathies. Neurology. 2012;79:2241-8.